Our Commitment: Science First. Always.
At Durand Health, we believe your health decisions should be guided by evidence, not marketing.
The health and wellness industry is experiencing a surge of premium screening products marketed directly to consumers and employers. From multi-cancer blood tests costing thousands of dollars to full-body MRI scans and direct-to-consumer longevity blood panels, the promise is compelling: detect disease before it starts.
We understand the appeal. Early detection saves lives. We have built our entire practice around prevention and early intervention.
But there is a critical difference between proven science and premature commercialization. And we believe Canadians deserve to know the difference.
Healthcare hype is not healthcare.
On February 21, 2026, the largest randomized controlled trial in the history of multi-cancer early detection reported that the leading test on the market failed its primary endpoint. 142,000 participants. Three years. NHS England. The New York Times ran the story on its front page:
“Grail’s Cancer Detection Test Fails in Major Study” — Rebecca Robbins and Gina Kolata, The New York Times, Section A, Page 1, February 21, 2026 https://www.nytimes.com/2026/02/20/health/cancer-detection-test-grail.html
Dr. Eric Topol, one of the most cited physician-scientists in the world, summarized the result plainly: “The trial is negative. End. Stop. Period.”
That was six weeks ago. As of today, the single premium Canadian clinic that locked up exclusive national distribution rights for GRAIL’s Galleri test is still actively promoting it on its homepage. Still selling it at more than double the US list price of $949. The test is not approved by Health Canada. Not approved by the FDA. Not endorsed by any professional medical society. A major Canadian insurer launched a partnership to offer it to policyholders eight days before the trial results were released. And nothing has changed.
We reviewed the critical warnings published in The Lancet in early 2024, which flagged the test’s low sensitivity for early-stage cancer (27.5% for stage 1-2), the false positive burden on health systems, and the absence of mortality data. We never considered offering this product. The science was never there. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02830-1/fulltext
This is part of a broader pattern in both the US and Canada that should concern every employer, every benefits professional, and every patient paying out of pocket for premium health services.
Full-body MRI scans costing $2,500 to $3,500+ CAD in Canada (and up to $4,499 USD in major US markets) are being marketed to healthy, asymptomatic patients despite the American College of Radiology, the American Academy of Family Physicians, and the FDA all declining to recommend them. No professional medical society in North America endorses full-body MRI screening for people without symptoms or risk factors.
And then there are the mass blood testing platforms. This is where Canadians and Americans need to pay very close attention.
A growing number of companies in both countries are selling “longevity” and “preventive” blood panels, some requiring 20 vials of blood drawn across two separate clinic visits. These are unfocused, blanket draws done in the absence of any patient history, prior bloodwork, or clinical intake, because these platforms lack the technology and the physician relationships to personalize what they order. Without knowing where you have been, they have no idea where to look. So they test everything. And they charge you for the privilege.
The testing itself is almost entirely standard laboratory bloodwork available from any accredited lab. There is nothing proprietary about it. And the vast majority of these biomarkers are already covered by government health insurance or employer benefits plans. In Canada, your family doctor can order comprehensive bloodwork and OHIP or your provincial plan covers virtually all of it. In the US, most employer health plans and Medicare cover standard preventive lab panels at no cost-sharing under the ACA.
You are not paying these companies for unique tests. You are paying for marketing, packaging, and an app.
Worse, these tests are fundamentally rearward-looking. They tell you what your biomarkers were on the day of the blood draw. A snapshot. Not a trajectory. And some of these platforms then generate a “biological age” score using Levine’s Phenotypic Age algorithm, which is a mathematical formula applied to nine standard clinical biomarkers that your family doctor already tests. This is not epigenetic analysis. It is not measuring DNA methylation or molecular aging. It is running a calculation on routine bloodwork and presenting it as longevity science. There is a meaningful difference between genuine epigenetic age measurement, which requires actual DNA methylation analysis at hundreds of specific genomic sites, and phenotypic age extrapolation from a basic blood panel. Most consumers do not know this. Most of these platforms do not explain it.
Some of these companies market themselves with impressive-sounding institutional affiliations, listing connections to leading universities, major health systems, and cancer hospitals. Look closer. In many cases these “affiliations” simply mean someone on their staff once worked at one of those institutions. That is not a research partnership. That is not a clinical collaboration. That is a resume line being used as a marketing asset.
Employers and individuals also need to ask hard questions about data privacy. Some of these platforms bury broad data licensing terms in their terms of service, granting themselves worldwide, perpetual rights to use your health data for product development, de-identified datasets, and marketing. In the US, many operate outside traditional HIPAA-covered relationships. In Canada, the regulatory framework for direct-to-consumer health data is often unclear. If you are an employer considering these platforms for your workforce, ask: who owns the data? Where does it go? Can it be resold?
Here is the bigger picture. US employer healthcare costs are projected to rise 9% to 9.5% in 2026, the highest single-year increase in over a decade, exceeding $17,000 per employee. On a compounded basis, costs are projected to be 62% higher than 2017 levels. Cancer is the number one condition driving employer costs for the fourth consecutive year. The system is broken, and it is broken because it operates on a break-fix model: wait until employees get sick, then spend enormous sums treating preventable conditions.
None of these hype-driven products fix that. A $2,000 cancer blood test that failed its trial does not fix it. A $3,500 full-body MRI that no medical society recommends does not fix it. A 20-vial blood draw through an app with no clinical follow-through does not fix it. These are expensive band-aids marketed as innovation.
What fixes it is a fundamentally different model. Continuous, preventive health intelligence that catches signals early, engages employees in their health over time, and navigates them to the right interventions before conditions become catastrophic and costly.
At Durand Future Health, we build exactly that. A Health Intelligence Platform that is forward-looking, not rearward-looking. We take the biological signals already available, add advanced testing where the science actually justifies it, including genuine epigenetic analysis, and wrap it in continuous, AI-driven care navigation that keeps employees engaged in their health for life. Physician-led. Evidence-based. Secure, with employee data never resold. Measured by outcomes, not by how many vials we can draw or how much we can charge for a single visit.
We help employers, insurers, and government payors move from the break-fix model that is bankrupting the system to a preventive, continuous guidance model that reduces spend, reduces productivity losses, and maximizes health outcomes for every dollar spent.
Outcomes over profit. Science over speed. Patients over shareholders.
We do not sell fear. We do not sell lottery tickets. We build health intelligence that compounds over time.
Durand® With You for Life®.
Evidence-based. Physician-led. Continuously evolving. For executives and all levels of staff.
Book a complimentary consultation to learn how Durand Health can serve your organization.
durandhealth.com | durand.life | 905-527-1342 | contact@durandhealth.com
